生活方式改变对严重高总胆固醇(> 14 mmol/L)和甘油三酯(> 40 mmol/L)患者的治疗

Janhavi Patel, Tanmya Sharma, Connor Allan, Gregory Curnew
{"title":"生活方式改变对严重高总胆固醇(> 14 mmol/L)和甘油三酯(> 40 mmol/L)患者的治疗","authors":"Janhavi Patel,&nbsp;Tanmya Sharma,&nbsp;Connor Allan,&nbsp;Gregory Curnew","doi":"10.15280/jlm.2021.11.1.43","DOIUrl":null,"url":null,"abstract":"<p><p>In this report, we describe a case of a 37-year old man who presented with a history of total cholesterol > 14 mmol/L and triglyceride levels > 40 mmol/L. The patient was initially thought to have familial hypercholesterolemia due to his elevated total cholesterol, by his family physician. He was prescribed evolucumab, a proprotein convertase subtilisin/ kexin type 9 inhibitor drug which has shown efficacy for lowering low-density lipoprotein-cholesterol levels, to reduce his high total cholesterol. However, in this patient, the elevated total cholesterol was likely due to hypertriglyceridemia, rather than increased low-density lipoprotein-cholesterol levels. Through this case we provide an approach for the clinical management of patients with elevated total cholesterol with underlying triglycerides ≥ 10 mmol/L. The primary intervention for management of triglycerides ≥ 10 mmol/L involves lifestyle modifications including, changes in diet, exercise, reduction in body mass index, and abstinence from alcohol consumption. Secondary intervention involves management through pharmacotherapy with fibrates and statins. Creating a plan of action with the patient, incorporating lifestyle modifications alone, the patient was able to reduce the triglycerides from an average of 44.94 mmol/L to 3.28 mmol/L.</p>","PeriodicalId":73805,"journal":{"name":"Journal of lifestyle medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a7/d7/jlm-11-1-43.PMC7957042.pdf","citationCount":"1","resultStr":"{\"title\":\"Use of Lifestyle Modifications for Management of a Patient with Severely High Total Cholesterol (> 14 mmol/L) and Triglycerides (> 40 mmol/L).\",\"authors\":\"Janhavi Patel,&nbsp;Tanmya Sharma,&nbsp;Connor Allan,&nbsp;Gregory Curnew\",\"doi\":\"10.15280/jlm.2021.11.1.43\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In this report, we describe a case of a 37-year old man who presented with a history of total cholesterol > 14 mmol/L and triglyceride levels > 40 mmol/L. The patient was initially thought to have familial hypercholesterolemia due to his elevated total cholesterol, by his family physician. He was prescribed evolucumab, a proprotein convertase subtilisin/ kexin type 9 inhibitor drug which has shown efficacy for lowering low-density lipoprotein-cholesterol levels, to reduce his high total cholesterol. However, in this patient, the elevated total cholesterol was likely due to hypertriglyceridemia, rather than increased low-density lipoprotein-cholesterol levels. Through this case we provide an approach for the clinical management of patients with elevated total cholesterol with underlying triglycerides ≥ 10 mmol/L. The primary intervention for management of triglycerides ≥ 10 mmol/L involves lifestyle modifications including, changes in diet, exercise, reduction in body mass index, and abstinence from alcohol consumption. Secondary intervention involves management through pharmacotherapy with fibrates and statins. Creating a plan of action with the patient, incorporating lifestyle modifications alone, the patient was able to reduce the triglycerides from an average of 44.94 mmol/L to 3.28 mmol/L.</p>\",\"PeriodicalId\":73805,\"journal\":{\"name\":\"Journal of lifestyle medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a7/d7/jlm-11-1-43.PMC7957042.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of lifestyle medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15280/jlm.2021.11.1.43\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of lifestyle medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15280/jlm.2021.11.1.43","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

在这个报告中,我们描述了一个37岁男性的病例,他的总胆固醇> 14 mmol/L,甘油三酯水平> 40 mmol/L。由于患者总胆固醇升高,家庭医生最初认为患者患有家族性高胆固醇血症。医生给他开了evolucumab,这是一种蛋白转化酶枯草杆菌素/克辛蛋白9型抑制剂药物,对降低低密度脂蛋白胆固醇水平有效,从而降低他的高总胆固醇。然而,在该患者中,总胆固醇升高可能是由于高甘油三酯血症,而不是低密度脂蛋白-胆固醇水平升高。通过本病例,我们为甘油三酯≥10 mmol/L的总胆固醇升高患者的临床管理提供了一种方法。管理甘油三酯≥10 mmol/L的主要干预措施包括改变生活方式,包括改变饮食、运动、降低体重指数和戒酒。二级干预包括通过贝特类药物和他汀类药物治疗。与患者一起制定行动计划,仅结合生活方式的改变,患者能够将甘油三酯从平均44.94 mmol/L降低到3.28 mmol/L。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Use of Lifestyle Modifications for Management of a Patient with Severely High Total Cholesterol (> 14 mmol/L) and Triglycerides (> 40 mmol/L).

Use of Lifestyle Modifications for Management of a Patient with Severely High Total Cholesterol (> 14 mmol/L) and Triglycerides (> 40 mmol/L).

In this report, we describe a case of a 37-year old man who presented with a history of total cholesterol > 14 mmol/L and triglyceride levels > 40 mmol/L. The patient was initially thought to have familial hypercholesterolemia due to his elevated total cholesterol, by his family physician. He was prescribed evolucumab, a proprotein convertase subtilisin/ kexin type 9 inhibitor drug which has shown efficacy for lowering low-density lipoprotein-cholesterol levels, to reduce his high total cholesterol. However, in this patient, the elevated total cholesterol was likely due to hypertriglyceridemia, rather than increased low-density lipoprotein-cholesterol levels. Through this case we provide an approach for the clinical management of patients with elevated total cholesterol with underlying triglycerides ≥ 10 mmol/L. The primary intervention for management of triglycerides ≥ 10 mmol/L involves lifestyle modifications including, changes in diet, exercise, reduction in body mass index, and abstinence from alcohol consumption. Secondary intervention involves management through pharmacotherapy with fibrates and statins. Creating a plan of action with the patient, incorporating lifestyle modifications alone, the patient was able to reduce the triglycerides from an average of 44.94 mmol/L to 3.28 mmol/L.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信